A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Drug: JNJ-53718678 500 mgDrug: JNJ-53718678 80 mgDrug: Placebo
- Registration Number
- NCT03379675
- Lead Sponsor
- Janssen Research & Development, LLC
- Brief Summary
The purpose of this study is to explore the antiviral effect of JNJ-53718678 at 2 dose levels (80 milligrams \[mg\] and 500 mg) once daily for 7 days in adults with Respiratory Syncytial Virus (RSV) infection, as measured by RSV viral load in nasal secretions by quantitative reverse transcription polymerase chain reaction (qRT-PCR) assay.
- Detailed Description
This study will be performed to explore the antiviral activity, clinical outcomes, safety, tolerability, and pharmacokinetics of JNJ-53718678 in adult participants infected with RSV. The study will include both participants who are otherwise healthy (ie, without underlying condition) or who have comorbid conditions (eg, asthma, chronic obstructive pulmonary disease (COPD), cardiovascular disease, other chronic diseases), with the exception of immunocompromised participants, presenting for medical care but not requiring hospitalization. The study will include a screening period (Day -1 to Day 1), a treatment Period (Day 1 to Day 8), and a follow-up period (Day 9 to Day 28). Safety evaluations will include adverse events, laboratory tests, electrocardiogram, vital signs, physical examination, and specific toxicities.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 72
- Participants must have an acute respiratory illness with signs and symptoms consistent with a viral infection (example, fever, cough, nasal congestion, runny nose, sore throat, myalgia, lethargy, shortness of breath, or wheezing) with onset less than or equal to 5 days from the anticipated time of randomization. Onset of symptoms is defined as the time the participant becomes aware of the first sign and/or symptom consistent with a viral infection
- Participant has been diagnosed with respiratory syncytial virus (RSV) infection using a rapid polymerase chain reaction (PCR) based or rapid-antigen-detection test
- Before randomization, a woman must be not of childbearing potential defined as: Premenarchal, Postmenopausal or Permanently sterile
- A male participant must agree to the use of acceptable contraceptive measures
- With the exception of the RSV-related illness the participant must be medically stable on the basis of physical examination, medical history, vital signs, and electrocardiogram (ECG) performed at screening
- Hospitalized participants or participants expected to be hospitalized within 24 hours of screening
- History of or concurrent illness (beyond a comorbid condition) that in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant or that could prevent, limit, or confound the protocol-specified assessments
- Participants who had major surgery within the 28 days prior to randomization or have planned major surgery through the course of the study
- Participants who are considered by the investigator to be immunocompromised within the past 12 months
- Participant has known or suspected chronic or acute hepatitis B or C infection
- Women who are pregnant or breastfeeding
- Participants with clinically significant abnormal ECG findings (other than QT-interval corrected for heart rate according to Fridericia [QTcF] interval greater than [>] 500 millisecond [ms]) not consistent with the underlying condition in the study population, as judged by the investigator
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Treatment A: JNJ-53718678 500 mg JNJ-53718678 500 mg Participants will receive 500 mg dose of JNJ-53718678 once daily for 7 days. Treatment B: JNJ-53718678 80 mg + Placebo JNJ-53718678 80 mg Participants will receive 80 mg dose of JNJ-53718678 along with the matching placebo to the same total volume as for the 500 mg dose once daily for 7 days. Treatment B: JNJ-53718678 80 mg + Placebo Placebo Participants will receive 80 mg dose of JNJ-53718678 along with the matching placebo to the same total volume as for the 500 mg dose once daily for 7 days. Treatment C: Placebo Placebo Participants will receive matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
- Primary Outcome Measures
Name Time Method Area Under the Respiratory Syncytial Virus (RSV) Viral Load (VL)-Time Curve (AUC) From Immediately Prior to First Dose of Study Drug (Baseline) Through Day 3 Baseline through Day 3 Area under the RSV VL-time curve (AUC) was determined as log10 copies\*hour per milliliter (Log10 copies\*hr/mL) by quantitative reverse transcription polymerase chain reaction (qRT-PCR) assay of mid turbine nasal swabs.
Area Under the RSV VL-time Curve (AUC) From Immediately Prior to First Dose of Study Drug (Baseline) Through Day 5 Baseline through Day 5 Area under the RSV VL-time curve (AUC) was determined as Log10 copies\*hr/mL by qRT-PCR assay of mid turbine nasal swabs.
Area Under the RSV VL-time Curve (AUC) From Immediately Prior to First Dose of Study Drug (Baseline) Through Day 8 Baseline through Day 8 Area under the RSV VL-time curve (AUC) was determined as Log10 copies\*hr/mL by qRT-PCR assay of mid turbine nasal swabs.
Area Under the RSV VL-time Curve (AUC) From Immediately Prior to First Dose of Study Drug (Baseline) Through Day 14 Baseline through Day 14 Area under the RSV VL-time curve (AUC) was determined as Log10 copies\*hr/mL by qRT-PCR assay of mid turbine nasal swabs.
Change From Baseline in RSV Viral Load at Day 3 Baseline to Day 3 Change from baseline in RSV viral load at Day 3 was measured as Log10 copies/mL by qRT-PCR assay in the mid-turbinate nasal swab specimens.
Change From Baseline in RSV Viral Load at Day 5 Baseline to Day 5 Change from baseline in RSV viral load at Day 5 was measured as Log10 copies/mL by qRT-PCR assay in the mid-turbinate nasal swab specimens.
Change From Baseline in RSV Viral Load at Day 8 Baseline to Day 8 Change from baseline in RSV viral load at Day 8 was measured as Log10 copies/mL by qRT-PCR assay in the mid-turbinate nasal swab specimens.
Change From Baseline in RSV Viral Load at Day 14 Baseline to Day 14 Change from baseline in RSV viral load at Day 14 was measured as Log10 copies/mL by qRT-PCR assay in the mid-turbinate nasal swab specimens.
Change From Baseline in RSV Viral Load at Day 21 Baseline to Day 21 Change from baseline in RSV viral load oat Day 21 was measured as Log10 copies/mL by qRT-PCR assay in the mid-turbinate nasal swab specimens.
RSV Viral Load at Baseline Baseline RSV viral load was measured as log10 copies/mL by qRT-PCR assay in the mid-turbinate nasal swab specimens.
RSV Viral Load at Day 3 Day 3 RSV viral load was measured as log10 copies/mL by qRT-PCR assay in the mid-turbinate nasal swab specimens.
RSV Viral Load at Day 5 Day 5 RSV viral load was measured as log10 copies/mL by qRT-PCR assay in the mid-turbinate nasal swab specimens.
RSV Viral Load at Day 8 Day 8 RSV viral load was measured as log10 copies/mL by qRT-PCR assay in the mid-turbinate nasal swab specimens.
RSV Viral Load at Day 14 Day 14 RSV viral load was measured as log10 copies/mL by qRT-PCR assay in the mid-turbinate nasal swab specimens.
RSV Viral Load at Day 21 Day 21 RSV viral load was measured as log10 copies/mL by qRT-PCR assay in the mid-turbinate nasal swab specimens.
Time to Undetectable RSV Viral Load Up to Day 21 The time to undetectable nasal RSV RNA viral load was defined as the time in days from initiation of study treatment until first post-baseline time point at which RSV RNA was undetectable and after which time there were no more detectable virus assessments.
Percentage of Participants With Undetectable RSV Viral Load at Day 3 Day 3 Percentage of participants with undetectable RSV viral load at Day 3 were reported.
Percentage of Participants With Undetectable RSV Viral Load at Day 5 Day 5 Percentage of participants with undetectable RSV viral load at Day 5 were reported.
Percentage of Participants With Undetectable RSV Viral Load at Day 8 Day 8 Percentage of participants with undetectable RSV viral load at Day 8 were reported.
Percentage of Participants With Undetectable RSV Viral Load at Day 14 Day 14 Percentage of participants with undetectable RSV viral load at Day 14 were reported.
Percentage of Participants With Undetectable RSV Viral Load at Day 21 Day 21 Percentage of participants with undetectable RSV viral load at Day 21 were reported.
- Secondary Outcome Measures
Name Time Method Number of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability Up to Day 28 An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
Number of Participants With Worst Treatment-Emergent Laboratory Abnormalities Up to Day 28 Number of participants with worst treatment-emergent laboratory abnormalities (serum chemistry, hematology and urinalyses) were reported based on DMID toxicity grading scale. DMID toxicity grade categorized as Grade 1=mild(mild discomfort (\< 48 hours); no medical intervention/therapy required), Grade 2= moderate (Moderate Mild to moderate limitation in activity - some assistance may be needed; no or minimal medical intervention/therapy required), Grade 3= severe (severe Marked limitation in activity, some assistance usually required; medical intervention/therapy required, hospitalizations possible), and Grade 4=life threatening (extreme limitation in activity, significant assistance required; significant medical intervention/therapy required, hospitalization or hospice care probable).
Number of Participants With Worst Treatment-Emergent Vital Sign Abnormalities Up to Day 28 Number of participants with worst treatment emergent vital sign abnormalities (including Systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]) as abnormally low, mild increased, moderate increased and severe increased were reported. SBP: Abnormally low- Less than or equal to (\<=) 50 mmHg, Grade 1 (mild)- 90 mmHg - \< 100 mmHg, Grade 2 (moderate)- greater than or equal to (\>=)100 mmHg to \< 110 mmHg, Grade 3 (severe)- \>=110 mmHg; DBP: Abnormally low- \<=90 mmHg, Grade 1 (mild)- 140 mmHg - \< 160 mmHg, Grade 2 (moderate)- \>=160 mmHg to \< 180 mmHg, Grade 3 (severe)- \>=180 mmHg.
Number of Participants With Worst Treatment-Emergent (TE) Electrocardiograms (ECGs) Abnormalities Up to Day 28 The number of participants with worst TE ECG abnormalities were reported. The ECG variables that were analyzed included heart rate, PR interval, QRS interval, QT interval, and corrected QT (QTc) interval. Parameters for abnormal ECG findings were QT interval corrected for heart rate (QTc) according to Bazett's formula (QTcB or Borderline Prolonged QTcB) Interval (\[450 milliseconds {ms}, 480 ms\], \[480 ms, 500 ms\], and \[more than 500 ms\]), QTc according to Fridericia's formula (QTcF or Borderline Prolonged QTcB) Interval (\[450 ms, 480 ms\], \[480 ms, 500 ms\], and \[more than 500 ms\]).
Peripheral Capillary Oxygen Saturation (SpO2) Over Time Baseline, Days 3, 8, 14, and 21 Peripheral capillary oxygen saturation was measured by the investigator over time.
Change From Baseline in Peripheral Capillary Oxygen Saturation Baseline to Days 3, 8, 14 and 21 Change from baseline in peripheral capillary oxygen saturation levels was calculated by the investigator.
Pulse Rate Over Time Baseline, Days 3, 8, 14 and 21 Pulse rate was measured by the investigator over time.
Change From Baseline in Pulse Rate Baseline to Days 3, 8, 14 and 21 Change from baseline in pulse rate was calculated and reported by the investigator.
Respiratory Rate Over Time Baseline, Days 3, 8, 14 and 21 Respiratory rate was measured by the investigator over time.
Change From Baseline in Respiratory Rate Baseline to Days 3, 8, 14 and 21 Change from baseline in respiratory rate was calculated and reported by the investigator.
Body Temperature Over Time Baseline, Days 3, 8, 14 and 21 Body temperature was measured over time. Participants were provided a thermometer and asked to record body temperature in the electronic device.
Change From Baseline in Body Temperature Baseline to Days 3, 5, 8, 14 and 21 Change from baseline in body temperature was calculated and reported. Participants were provided a thermometer and asked to record body temperature in the electronic device.
Area Under the Plasma Concentration-Time Curve From Time Point 0 Hours Until 24 Hours Post Dose 0 to 24 hours post dose on Days 1 and 7 AUC (0-24) is defined as area under the plasma concentration-time curve from time point 0 hours until 24 hours post dose.
Severity of Signs and Symptoms of RSV Assessed by Respiratory Infection-Patient Reported Outcomes (RI-PRO) Questionnaire Baseline, Days 3, 5, 8, 14 and 21 The severity of signs and symptoms of RSV infection was assessed using the RI-PRO questionnaire. The RI-PRO questionnaire is 32-item questionnaire. It summarizes severity of 6 symptom domains: nose (4 items), throat (3 items), eyes (3 items), chest/respiratory (7 items), gastrointestinal (4 items), and body/systemic (11 items). Each RI-PRO domain score ranges from 0 (symptom free) to 4 (very severe symptoms). Domain scores were calculated as the arithmetic mean of the scores for items within the domain.
Duration of Signs and Symptoms of RSV Assessed by RI-PRO Baseline up to Day 21 Duration of signs and symptoms of RSV infection was assessed by the time to resolution of all RSV symptoms from RI-PRO questionnaire. Resolution was defined as a score of 'Not at all/symptom-free' (score=0) or 'A little bit' (score=1) for at least 24 hours. The RI-PRO questionnaire is a 32-item questionnaire. It summarizes severity of 6 symptom domains: nose (4 items), throat (3 items), eyes (3 items), chest/respiratory (7 items), gastrointestinal (4 items) and body/systemic (11 items). Each RI-PRO score ranges from 0 (symptom-free) to 4 (very severe symptoms).
Time to Resolution of Key RSV Symptoms as Assessed by RI-PRO Questionnaire Up to Day 21 Time to resolution of key RSV symptoms (congested or stuffy nose, sore or painful throat, trouble breathing, chest tightness, coughing, coughed up mucus or phlegm, weak or tired) as assessed by RI-PRO questionnaire was reported. Resolution of RSV symptoms was defined as a score of 'Not at all/symptom free' (score = 0) or 'A little bit' (score = 1) for at least 24 hours for symptoms of the RI-PRO questionnaire. The RI-PRO questionnaire is 32-item questionnaire. It summarizes severity of 6 symptom domains: nose (4 items), throat (3 items), eyes (3 items), chest/respiratory (7 items), gastrointestinal (4 items), and body/systemic (11 items). Each RI-PRO score ranges from 0 (symptom-free) to 4 (very severe symptoms).
Time to Return to Usual Activity/Health Based on RI-PRO Questionnaire Up to Day 21 Time from the first dose of study drug until the time to return to usual activity/health was determined. Return to usual activity/health when the response is 'Yes' on RI-PRO additional question 7 ('Have you returned to your usual activity/health today?') for at least 24 hours.
Predose Plasma Concentration (Ctrough) of JNJ-53718678 Predose on Days 1 and 7 Ctrough is the trough plasma concentration of JNJ-53718678 estimated by population PK model.
Maximum Plasma Concentration (Cmax) of JNJ-53718678 Days 1 and 7 Cmax is the maximum plasma concentration of JNJ-53718678 estimated by population PK model.
Trial Locations
- Locations (124)
CHU Saint-Pierre
🇧🇪Bruxelles, Belgium
Jaak Mortelmans
🇧🇪Ham, Belgium
BVBA Dr. Luc Capiau
🇧🇪Massemen, Belgium
Westmead Hospital
🇦🇺Sydney, Australia
Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da PUCRS
🇧🇷Porto Alegre, Brazil
Fundacao para o Desenvolvimento Medico Hospitalar (UNESP Botucatu)
🇧🇷Botucatu, Brazil
Universidade Federal de Santa Catarina
🇧🇷Florianopolis, Brazil
Testumed
🇧🇪Tessenderlo, Belgium
Santa Casa de Misericordia de Belo Horizonte
🇧🇷Belo Horizonte, Brazil
Centro de Estudos e Pesquisas em Moléstias Infecciosas - CEPCLIN
🇧🇷Natal, Brazil
Associacao Hospitalar Beneficente Sao Vicente de Paulo - Hospital Sao Vicente de Paulo
🇧🇷Passo Fundo, Brazil
Hosp. Univ. Virgen de Las Nieves
🇪🇸Granada, Spain
Hosp. Univ. de La Princesa
🇪🇸Madrid, Spain
Hosp. Clinico Univ. de Santiago
🇪🇸Santiago de Compostela, Spain
Hosp. Alvaro Cunqueiro
🇪🇸Vigo, Spain
Skanes universitetssjukhus
🇸🇪Malmö, Sweden
Norrlands Universitetssjukhus
🇸🇪Umeå, Sweden
Akademiska Sjukhuset
🇸🇪Uppsala, Sweden
Shin Yukuhashi Hospital
🇯🇵Yukuhashi, Japan
Paratus Clinical Kippa Ring Clinic
🇦🇺Kippa Ring, Australia
Taipei Medical University Shuang Ho Hospital
🇨🇳New Taipei, Taiwan
Toyota Kosei Hospital
🇯🇵Toyota, Japan
Mater Hospital Brisbane
🇦🇺South Brisbane, Australia
Paratus Clinical Kanwal Clinic
🇦🇺Kanwal, Australia
Kuang Tien General Hospital- Dajia
🇨🇳Taichung City, Taiwan
Core Healthcare Group
🇺🇸Cerritos, California, United States
eStudySite
🇺🇸Chula Vista, California, United States
SC Clinical Research Inc
🇺🇸Garden Grove, California, United States
Lake Internal Medicine Associates
🇺🇸Eustis, Florida, United States
Florida Research Center Inc.
🇺🇸Miami, Florida, United States
Family Medicine
🇺🇸Nampa, Idaho, United States
William Beaumont Hospital
🇺🇸Royal Oak, Michigan, United States
AllinaHealth - Abbott Northwestern Hospital (13520)
🇺🇸Minneapolis, Minnesota, United States
Mercury Street Medical Group, PLLC
🇺🇸Butte, Montana, United States
Onsite Clinical Solutions
🇺🇸Charlotte, North Carolina, United States
Unity Clinical Research
🇺🇸Lindsay, Oklahoma, United States
Spectrum Medical Research
🇺🇸Gaffney, South Carolina, United States
Fusion Clinical Research of Spartanburg
🇺🇸Spartanburg, South Carolina, United States
Hospital Espanol De Bahia Blanca
🇦🇷Bahia Blanca, Argentina
Hospital Interzonal General de Agudos Dr. Jose Penna
🇦🇷Bahia Blanca, Argentina
Hospital Privado - Centro Medico de Cordoba
🇦🇷Barrio Parque Velez Sarfield, Argentina
Fundación Respirar
🇦🇷Caba, Argentina
Hospital Italiano de La Plata
🇦🇷Ciudad De La Plata, Argentina
HIGA Prof. Dr. Ramón Carrillo
🇦🇷Ciudadela, Argentina
Hospital Rawson
🇦🇷Cordoba, Argentina
Hospital Italiano de Cordoba
🇦🇷Cordoba, Argentina
Hospital Cordoba
🇦🇷Cordoba, Argentina
Sanatorio Juan XXIII
🇦🇷General Roca, Argentina
Instituto Médico de la Fundación de Estudios Clínicos (ECLIN)
🇦🇷Rosario, Argentina
Clinica Mayo de UMCB
🇦🇷San Miguel de Tucuman, Argentina
Paratus Clinical Blacktown Clinic
🇦🇺Blacktown, Australia
Barwon Health - University Hospital Geelong
🇦🇺Geelong, Australia
Universidade Federal da Bahia - Hospital Professor Edgard Santos
🇧🇷Salvador, Brazil
Hospital Alemao Oswaldo Cruz
🇧🇷Sao Paulo, Brazil
Hospital Heliopolis
🇧🇷Sao Paulo, Brazil
Sociedade Beneficente de Senhoras - Hospital Sírio Libanês
🇧🇷São Paulo, Brazil
MHAT 'Sv. Ivan Rilski' Kozloduy EOOD
🇧🇬Kozloduy, Bulgaria
Specialized Hospital for Active Treatment of Pulmonary Diseases - Pernik
🇧🇬Pernik, Bulgaria
SHAT of Pneumo-phthisiatric Diseases Dr Dimitar Gramatikov - Ruse, EOOD
🇧🇬Ruse, Bulgaria
MHAT 'Dr. Bratan Shukerov'
🇧🇬Smolyan, Bulgaria
Diagnostic Consultation Centre 'Alexandrovska' EOOD
🇧🇬Sofia, Bulgaria
Specialized Hospital for Active Treatment of Pulmonary Diseases - Troyan EOOD
🇧🇬Troyan, Bulgaria
Aggarwal and associates Ltd
🇨🇦Brampton, Ontario, Canada
Milestone Research
🇨🇦London, Ontario, Canada
Dr Anil K Gupta Medicine Professional Corporation
🇨🇦Toronto, Ontario, Canada
Clinique Force Medic (GCP Trials)
🇨🇦Montreal, Quebec, Canada
Centre Hospitalier d'Agen
🇫🇷Agen cedex 9, France
Cabinet du Dr Remaud
🇫🇷Angers, France
Maison Medicale Rive Sud
🇫🇷Murs Erigne, France
CHU Nantes - Hotel Dieu
🇫🇷Nantes, France
Cabinet du Dr Boye
🇫🇷Nantes, France
Cabinet du Dr Baranes
🇫🇷Paris, France
MECS GmbH
🇩🇪Berlin, Germany
IKF Pneumologie GmbH & Co. KG Am Standort IFS - Interdisziplinäres Facharztzentrum
🇩🇪Frankfurt, Germany
Klinische Forschung Hannover-Mitte GmbH
🇩🇪Hannover, Germany
Hausarztpraxis am Lindenplatz
🇩🇪Luebeck, Germany
Fukui General Clinic
🇯🇵Fukui-shi, Japan
Koukan Clinic
🇯🇵Kawasaki, Japan
Shinkomonji hospital
🇯🇵Kitakyusyu, Japan
Musashikoganei Clinic
🇯🇵Koganei-Shi, Japan
Medical Square Kuhonji Clinic
🇯🇵Kumamoto-shi, Japan
Rinku General Medical Center
🇯🇵Osaka, Japan
Tokyo Shinagawa Hospital
🇯🇵Shinagawa-ku, Japan
Saino Clinic
🇯🇵Tokorozawa-shi, Japan
Soonchunhyang University Bucheon Hospital
🇰🇷Bucheon, Korea, Republic of
Kyungpook National University Hospital
🇰🇷Daegu, Korea, Republic of
The Catholic university of Korea, St. Vincent's Hospital
🇰🇷Gyeonggi-do, Korea, Republic of
Gachon University Gil Hospital
🇰🇷Incheon, Korea, Republic of
Inha University Hospital
🇰🇷Incheon, Korea, Republic of
Kangnam Sacred Heart Hospital
🇰🇷Seoul, Korea, Republic of
Seoul Metropolitan Government Seoul National University Boramae Medical Center
🇰🇷Seoul, Korea, Republic of
Hospital Cardiologica Aguascalientes
🇲🇽Aguascalientes, Mexico
Centro de Investigacion Medico Biologica y Terapia Avanzada CIMBYTA
🇲🇽Guadalajara, Mexico
Hospital Civil de Guadalajara Fray Antonio Alcalde
🇲🇽Guadalajara, Mexico
RM Pharma Specialists
🇲🇽Mexico, Mexico
Hospital Universitario de Nuevo Leon 'Dr Jose Eleuterio Gonzalez'
🇲🇽Monterrey, Mexico
Indywidualna Specjalistyczna Praktyka Lekarska Lek. Krzysztof Lis
🇵🇱Kielce, Poland
Centrum Medyczne All Med
🇵🇱Krakow, Poland
Diamond Clinic
🇵🇱Krakow, Poland
SPZOZ Uniwersytecki Szpital Kliniczny nr 1 im.Barlickiego Uniwersytetu Med. w Lodzi Zespol Poradni
🇵🇱Lodz, Poland
Beata Asankowicz-Bargiel i Partnerzy, Lekarze-sp. Spec. Poradnia Pulmonologiczna
🇵🇱Ostrow Wielkopolski, Poland
Centrum Badan Klinicznych, Osrodek Badan Wczesnej Fazy
🇵🇱Wroclaw, Poland
Krasnogorsk city hospital #1
🇷🇺Krasnogorsk, Russian Federation
City Polyclinic #25 of the Nevsky District of SPB
🇷🇺Saint-Petersburg, Russian Federation
LLC 'Medical centr 'Reavita Med Spb'
🇷🇺Saint-Petersburg, Russian Federation
Eco-safety Ltd
🇷🇺Saint-Petersburg, Russian Federation
Research Institute of Influenza
🇷🇺St. Petersburg, Russian Federation
Soweto Clinical Trial Centre
🇿🇦Johannesburg, South Africa
Newtown Clinical Research
🇿🇦Johannesburg, South Africa
Emmed Research
🇿🇦Pretoria, South Africa
Welkom Clinical Trial Centre
🇿🇦Welkom, South Africa
Hosp. Gral. Univ. de Alicante
🇪🇸Alicante, Spain
Hosp. Gral. Univ. de Elche
🇪🇸Elche, Spain
Kaohsiung Veterans General Hospital
🇨🇳Kaohsiung, Taiwan
Far Eastern Memorial Hospital
🇨🇳Taipei City, Taiwan
Taipei Municipal Wanfang Hospital
🇨🇳Taipei, Taiwan
Medical Center of LL Company 'Scientific Medical Center-Your Doctor'
🇺🇦Kharkiv, Ukraine
Medical Unit Of Company 'Kharkiv Tractor Plant', Kharkiv Medical Academy Of Postgraduate Education
🇺🇦Kharkiv, Ukraine
Mi 'Kherson City Clinical Hospital Of E.E. Karabelesh'
🇺🇦Kherson, Ukraine
Kyiv Railway Clinical Hospital #2 Of Branch 'Health Center' Of The Company 'Ukrainian Railway'
🇺🇦Kyiv, Ukraine
Policlinic of State Joint Stock Holding Company 'Artem'
🇺🇦Kyiv, Ukraine
Private Small Enterprise Medical Center Pulse
🇺🇦Vinnytsia, Ukraine
Medical Center Ltd 'Health Clinic', Department Of General Therapy
🇺🇦Vinnytsya, Ukraine
Vinnytsia City Clinical Hospital #1, Vinnytsia National Medical University
🇺🇦Vinnytsya, Ukraine